Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Rhea-AI Summary
Acrivon (Nasdaq: ACRV) will present three preclinical posters at AACR 2026 (April 19–20) showing strong synergies of ACR-368 and ACR-2316 with anti-PD-L1 checkpoint inhibitors and synergy of ACR-368 with Topo 1 ADC payloads. Posters detail durable immune memory and rationale for frontline combination development.
Poster numbers: 239 (Apr 19), LB152 (Apr 20 AM), 3789 (Apr 20 PM).
Positive
- None.
Negative
- None.
News Market Reaction – ACRV
On the day this news was published, ACRV gained 4.49%, reflecting a moderate positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $69.35M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector scanner flagged mixed momentum: peers like PSTV and TELO were up ~7.4–7.5%, while TPST and BCAB were down ~5.7–12.08%. With ACRV flat (0% change) pre-announcement, its setup differed from these more volatile peers despite broader biotech churn.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Clinical data update | Positive | -34.6% | Interim ACR-368 Phase 2b data and initial ACR-2316 results across pipeline. |
| Jan 06 | Clinical update preview | Positive | +31.4% | Announcement of upcoming webcast with ACR-368 and ACR-2316 clinical updates. |
| Dec 17 | Pipeline webcast plan | Neutral | -4.5% | Planned January 2026 webcast detailing ACR-368 and ACR-2316 trial updates. |
| Dec 17 | Clinical plans outlined | Neutral | -4.5% | Notice of forthcoming clinical update on Phase 2b ACR-368 and Phase 1 ACR-2316. |
| Oct 22 | Preclinical AACR-NCI data | Positive | +0.5% | AACR-NCI-EORTC posters on AP3 platform and differentiated ACR-2316 preclinical data. |
Clinical-trial-tagged news has shown volatile and often contrarian reactions, including a large selloff on strong ACR-368 data.
Over the past six months, Acrivon has repeatedly highlighted clinical progress for ACR-368 and ACR-2316. In October 2025, preclinical ACR-2316 data and early clinical activity coincided with a small gain. Through December 2025 and January 2026, a series of clinical-update announcements produced both double‑digit moves up and down, including a -34.58% reaction to positive Phase 2b and ACR-2316 data on Jan 8, 2026. Today’s AACR preclinical combination poster update fits that pattern of AP3‑guided oncology development milestones.
Historical Comparison
Clinical-trial-tagged ACRV news has averaged a -2.35% move, with both sharp rallies and selloffs. Today’s preclinical AACR combo poster update came as the stock sat unchanged, a calmer setup than prior data-heavy disclosures.
Recent clinical-trial-tagged releases trace ACR-368 from interim Phase 2b data toward a planned confirmatory Phase 3, while ACR-2316 advanced from preclinical differentiation to initial Phase 1 activity, with AP3-guided candidate expansion.
Market Pulse Summary
This announcement details AACR 2026 posters showing synergies for ACR-368 and ACR-2316 with anti‑PD‑L1 and Topo 1 ADC payloads, extending Acrivon’s AP3‑guided combination strategy. Prior clinical‑trial‑tagged updates have triggered both sharp gains and selloffs, including a -34.58% move on strong ACR-368 data. Investors may focus on how these preclinical findings support existing Phase 2b and Phase 1/2 programs and on future readouts that demonstrate clinical benefit from these combinations.
Key Terms
anti-pd-l1 medical
immune checkpoint inhibitors medical
antibody-drug conjugates medical
topoisomerase 1 medical
chk1/2 inhibitor medical
wee1/pkmyt1 inhibitor medical
adc payload medical
phase 2b medical
AI-generated analysis. Not financial advice.
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Data supports potential for frontline clinical combinations of ACR-368 and ACR-2316 with immune checkpoint inhibitors and of ACR-368 with Topo 1 antibody-drug conjugates (ADCs)
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced preclinical data that showed powerful synergies between its two lead assets and emerging and foundational standard-of-care anti-cancer agents. Both ACR-368, a CHK1/2 inhibitor currently in a registrational-intent Phase 2b study, and ACR-2316, a WEE1/PKMYT1 inhibitor currently in a Phase 1/2 study, showed strong synergy in combination with anti-PD-L1 checkpoint inhibition. Additionally, ACR-368 synergized with a Topo 1 inhibitor, a payload commonly used in ADCs. The data will be presented at the AACR 2026 Annual Meeting being held in San Diego, CA.
“We are excited to be presenting these highly actionable data, mechanistically derived from our AP3 platform, at AACR,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. “Our findings highlight attractive opportunities for future frontline development of ACR-368 and ACR-2316 in combination with immune checkpoint inhibitors and ADCs.”
The posters can be found on the Acrivon website under “Posters and Presentations” or by using this LINK.
Poster Presentation Details:
| Title | Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy |
| Date and Time | Sunday, April 19, 2026; 2:00 p.m. - 5:00 p.m. PT |
| Session | Experimental and Molecular Therapeutics: DNA Damage and Repair 1 |
| Poster Number | 239 |
| Title | ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy |
| Date and Time | Monday, April 20, 2026; 9:00 a.m. - 12:00 p.m. PT |
| Session | Late-Breaking Research: Immunology 2 |
| Poster Number | LB152 |
| Title | Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory |
| Date and Time | Monday, April 20, 2026; 2:00 p.m. - 5:00 p.m. PT |
| Session | Clinical Research: Combination Immunotherapies |
| Poster Number | 3789 |
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1/2 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840 and other potential development candidates targeting CDK11.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
